Domingo Gargallo-Viola has been elected to be part of the Executive Board of the BEAM Alliance!

Launched in June 2015, the BEAM Alliance (Biotech companies from Europe innovating in Anti-Microbial resistance research) represents over 70 small and medium-sized European companies involved in developing innovative products and kits to tackle antimicrobial resistance (AMR), including small molecule antibiotics, biologics, products with a prophylaxis indication, microbiome-based and phage-based therapies, immune targeting therapies, anti-biofilm agents and medical devices including in vitro diagnostics.